Aspen Neuroscience has announced plans to commence a first patient screening study of its therapeutic development candidate, ANPD001, to potentially treat idiopathic Parkinson’s disease (PD).

A lead product of the company, ANPD001 is an autologous neuron replacement therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company will collaborate with various clinical screening sites in the US in this regard.

The Trial-Ready Cohort Study is an initial step for the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration for ANPD001, the company noted.

It will offer data to and monitor potential subjects for the planned Phase I/IIa, first-in-patient clinical trial of ANPD001. 

The firm plans to announce multiple screening sites in the US throughout the spring.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aspen president and CEO Damien McDevitt said: “This is a historic moment for patients and for the Aspen Neuroscience team, as we open our first screening study to expedite our investigation of iPSC-derived cell replacement therapies for Parkinson’s disease. 

“This is a significant step forward for the patient community, for health care providers and the neuroscience field.”

A second most common neurodegenerative disease, PD impacts over ten million people globally. 

Aspen focuses on the development of tailored cell replacement that can eradicate the requirement for immunosuppressive therapy. 

This method utilises skin cell-derived iPSCs of the patient to make replacement dopamine neurons, which will be transplanted back into the patient. 

Before transplantation for clinical usage, each patient’s cells developed from a skin biopsy will be analysed using artificial intelligence-based genomics tools.

In April 2020, Aspen raised $70m in a Series A funding round to progress the development of its autologous neuron replacement therapy for Parkinson’s.